Using Doxepin for Urticaria

Urticaria Clinical Trial

Official title:

The Use of Doxepin for Urticaria in the Emergency Department

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05115136
• Other study ID #: 1576028
• Status: Recruiting
• Phase: Phase 3
• Start date: May 23, 2022
• Est. completion date: July 1, 2023

Study information

• Verified date: May 2022
• Source: State University of New York - Upstate Medical University
• Contact: David Andonian, MD
• Phone: 315-464-4363
• Email: andoniad[@]upstate.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Isolated urticaria in the emergency department is widely treated by physicians with histamine blocking agents such as diphenhydramine, cetirizine, and cimetidine. Doxepin is a tricyclic antidepressant that has been shown to have much higher concentrations of histamine blocking activity and therefore may be useful in treating urticaria. The purpose of this study is to compare the effectiveness of using doxepin verses a traditional medication, diphenhydramine (Benadryl), in the treatment of isolated urticaria in the emergency department.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: July 1, 2023
• Est. primary completion date: January 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Between 18-65 years of age

• Presenting to Upstate Adult Emergency Department at either the Downtown or Community campuses.

• Diagnosed with isolated/acute urticaria

• Requires treatment with antihistamines to alleviate symptoms

Exclusion Criteria:

• Pregnant women

• Prisoners

• Patients with altered mental status/have impaired decision-making capacity.

• Presenting with symptoms suggesting life threatening illness or anaphylaxis.

• Patients who have received any antihistamine (H1 antagonist) within the past 2 hours via any route of administration.

• Patients who have received an H2 antagonist within the past 2 hours.

• Patient received steroids by any route within the past 4 hours.

• Patient received epinephrine within the past 20 minutes.

• Patients currently taking concomitant p-glycoprotein inhibitors.

• Patients on any of the following CYP2D6 inhibitors: Bupropion, Fluoxetine, Paroxetine, Quinidine, Tipranavir.

• Patients with a history of serotonin syndrome.

• Patients currently taking another tricyclic antidepressant, selective serotonin reuptake inhibitor, and/or serotonin-norepinephrine reuptake inhibitor.

• Patients who have a condition where an antihistamine may be contraindicated.

• Patients with a contraindication to anticholinergic medications.

• History of adverse effects to tricyclic antidepressants or antihistamines.

• Patient who, based on their medical history or in the opinion of the clinician, have chronic urticaria, urticaria refractory to antihistamines, or dermatological disease that interferes with evaluation of a therapeutic response.

• Patients taking antileukotriene compounds (montelukast), calcineurin inhibitors (tacrolimus) or anti-serotonin agents (cyproheptadine)

Related Conditions & MeSH terms

• Urticaria

Intervention

Drug:
• Doxepin
25mg dose of Doxepin will be administered one time, by mouth
• Diphenhydramine
50 mg dose of Diphenhydramine will be administered one time, by mouth

Locations

Country	Name	City	State
United States	SUNY Upstate Medical University	Syracuse	New York

Sponsors (1)

Lead Sponsor	Collaborator
State University of New York - Upstate Medical University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement of urticaria	Improvement of urticaria based on pruritis score. Scale is from 1-5, lower the score the better.	1 hour after med administration, 2 hours after administration, and prior to discharge.
Primary	Improvement of urticaria	Improvement of urticaria based percent of body area affected. Scale being utilized is the % of body area chart.	1 hour after med administration, 2 hours after administration, and prior to discharge